Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? A Narrative Review

The majority of disease-modifying drugs (DMDs) available for the management of active relapsing–remitting multiple sclerosis (RMS) depend on continuous drug intake for maintained efficacy, with escalation to a more active drug when an unacceptable level of disease activity returns. Among continuousl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurol Ther
Main Authors: AlSharoqi, Isa Ahmed, Aljumah, Mohamed, Bohlega, Saeed, Boz, Cavit, Daif, Abdelkader, El-Koussa, Salam, Inshasi, Jihad, Kurtuncu, Murat, Müller, Thomas, Retief, Chris, Sahraian, Mohammad Ali, Shaygannejad, Vahid, Slassi, Ilham, Taha, Karim, Zakaria, Magd, Sørensen, Per Soelberg
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2020
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7229056/
https://ncbi.nlm.nih.gov/pubmed/32297127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40120-020-00187-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados